Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared Martin Gutierrez’s, Chief Scientific Officer at Outcomes Matter Innovations, Director, Phase I Program & Co-Chair of Thoracic Oncology at Hackensack Meridian Health, post on LinkedIn, adding:
“Phase 1 oncology is not the last resort. It’s the academic and intellectual frontier building the standard of care of 2030.
If you want to learn all the potential MOA before phase 2-3: STING agonists, trispecific T-cell engagers, next-gen ADCs, KRAS pan-RAS inhibitors, CAR-T/CAR-NK, and radioligand therapies.
If any of this is your space at ASCO26, find our team at booth 11022.”
Quoting Martin Gutierrez’s post:
“Join me at ASCO26!
Our Phase I Oncology Research Team invites you to visit booth 11022. Let’s discuss the future of cancer care through innovative Phase I trials.”
Other articles featuring Miguel Gonzalez Velez on OncoDaily.